Clinical Trials Browser

INDUSTRY × mavorixafor × Lymphoid × Clear all

NCT04274738 2024-08-27

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Phase 1 Completed

Waldenstrom Macroglobulinemia